Research
Hormonal
Incretin-based therapies are effective but present limitations for long-term obesity management.
Practitioners should be aware of the limitations of incretin therapies in long-term obesity management.
StrongQualifiesmedium confidence
Incretin-based therapies are effective but present limitations for long-term obesity management.
Why this rating
The claim is based on a synthesis of current evidence.
Source
Beyond incretin therapy: integrating precision nutrition for sustained obesity management medications
C.F. Nicoletti et al. · Obesity Medicine · 2026
DOI 10.1016/j.obmed.2026.100690
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →